Eris Lifesciences Limited (ERIS.NS)
INR 1384.8
(1.85%)
INR 1384.8
(1.85%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 4.94 Billion INR | -38.14% |
| 2022 | 8.89 Billion INR | 38.97% |
| 2021 | 6.4 Billion INR | 13.93% |
| 2020 | 5.62 Billion INR | 1.09% |
| 2019 | 5.55 Billion INR | 10.95% |
| 2018 | 5.01 Billion INR | 18.49% |
| 2017 | 4.22 Billion INR | 13.5% |
| 2016 | 3.72 Billion INR | 8.86% |
| 2015 | 3.42 Billion INR | -0.33% |
| 2014 | 3.43 Billion INR | 9.3% |
| 2013 | 3.14 Billion INR | 35.77% |
| 2012 | 2.31 Billion INR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 1.56 Billion INR | -13.92% |
| 2024 Q2 | 3.68 Billion INR | 5.26% |
| 2023 Q4 | 1.81 Billion INR | -31.34% |
| 2023 Q1 | 2.52 Billion INR | 5.3% |
| 2023 Q3 | 2.64 Billion INR | -0.77% |
| 2023 FY | 5.5 Billion INR | -38.14% |
| 2023 Q2 | 2.66 Billion INR | 5.57% |
| 2022 Q3 | 2.21 Billion INR | -2.22% |
| 2022 Q4 | 2.4 Billion INR | 8.26% |
| 2022 Q1 | 2.01 Billion INR | 30.94% |
| 2022 FY | 8.89 Billion INR | 38.97% |
| 2022 Q2 | 2.26 Billion INR | 12.72% |
| 2021 Q2 | 1.62 Billion INR | -0.43% |
| 2021 Q4 | 1.53 Billion INR | -5.03% |
| 2021 FY | 6.4 Billion INR | 13.93% |
| 2021 Q1 | 1.62 Billion INR | 29.21% |
| 2021 Q3 | 1.61 Billion INR | -0.17% |
| 2020 Q3 | 1.51 Billion INR | 3.23% |
| 2020 Q2 | 1.47 Billion INR | 7.63% |
| 2020 Q1 | 1.36 Billion INR | 4.03% |
| 2020 Q4 | 1.25 Billion INR | -17.11% |
| 2020 FY | 5.62 Billion INR | 1.09% |
| 2019 Q2 | 1.36 Billion INR | 2.73% |
| 2019 FY | 5.55 Billion INR | 10.95% |
| 2019 Q3 | 1.54 Billion INR | 13.34% |
| 2019 Q4 | 1.31 Billion INR | -15.09% |
| 2019 Q1 | 1.32 Billion INR | 9.53% |
| 2018 Q1 | 1.3 Billion INR | 14.28% |
| 2018 Q4 | 1.21 Billion INR | -2.98% |
| 2018 FY | 5.01 Billion INR | 18.49% |
| 2018 Q2 | 1.27 Billion INR | -2.32% |
| 2018 Q3 | 1.25 Billion INR | -1.91% |
| 2017 FY | 4.22 Billion INR | 13.5% |
| 2017 Q4 | 1.14 Billion INR | 13.28% |
| 2017 Q1 | 909.36 Million INR | 4.64% |
| 2017 Q2 | 1.16 Billion INR | 28.41% |
| 2017 Q3 | 1 Billion INR | -13.59% |
| 2016 Q1 | 833.15 Million INR | 0.0% |
| 2016 Q3 | 959.74 Million INR | -9.8% |
| 2016 FY | 3.72 Billion INR | 8.86% |
| 2016 Q4 | 869.05 Million INR | -9.45% |
| 2016 Q2 | 1.06 Billion INR | 27.71% |
| 2015 FY | 3.42 Billion INR | -0.33% |
| 2014 FY | 3.43 Billion INR | 9.3% |
| 2013 FY | 3.14 Billion INR | 35.77% |
| 2012 FY | 2.31 Billion INR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 15.86 Billion INR | 68.853% |
| Hester Biosciences Limited | 908.84 Million INR | -443.874% |
| Aarti Drugs Limited | 1.16 Billion INR | -323.386% |
| Aarti Pharmalabs Limited | 3.07 Billion INR | -60.777% |
| Albert David Limited | 1.02 Billion INR | -381.699% |
| Alembic Limited | 872.45 Million INR | -466.553% |
| Alkem Laboratories Limited | 32.83 Billion INR | 84.946% |
| Bafna Pharmaceuticals Limited | 455.58 Million INR | -984.965% |
| Bajaj HealthCare Limited | 985.34 Million INR | -401.646% |
| Biofil Chemicals and Pharmaceuticals Limited | 6.82 Million INR | -72377.126% |
| Brooks Laboratories Limited | 51.18 Million INR | -9557.952% |
| FDC Limited | 3.49 Billion INR | -41.237% |
| Glenmark Life Sciences Limited | 11.64 Billion INR | 57.537% |
| Gufic Biosciences Limited | 1.18 Billion INR | -316.567% |
| Hikal Limited | 4.46 Billion INR | -10.734% |
| Ind-Swift Limited | 946.56 Million INR | -422.197% |
| Innova Captab Limited | 931.03 Million INR | -430.911% |
| IOL Chemicals and Pharmaceuticals Limited | 2.2 Billion INR | -124.577% |
| Jagsonpal Pharmaceuticals Limited | 438.55 Million INR | -1027.11% |
| Jubilant Pharmova Limited | 14.45 Billion INR | 65.802% |
| Lincoln Pharmaceuticals Limited | 1.07 Billion INR | -360.157% |
| Lupin Limited | 125.09 Billion INR | 96.049% |
| Mangalam Drugs & Organics Limited | 162.22 Million INR | -2946.909% |
| Medico Remedies Limited | 59.67 Million INR | -8183.1% |
| Morepen Laboratories Limited | 1.98 Billion INR | -148.708% |
| Nectar Lifesciences Limited | 932.7 Million INR | -429.96% |
| Orchid Pharma Limited | 800.77 Million INR | -517.273% |
| Procter & Gamble Health Limited | 2.99 Billion INR | -65.018% |
| RPG Life Sciences Limited | 1.63 Billion INR | -202.228% |
| Kilitch Drugs (India) Limited | 412.42 Million INR | -1098.501% |
| Sigachi Industries Limited | 579.88 Million INR | -752.397% |
| Solara Active Pharma Sciences Limited | 2.55 Billion INR | -93.53% |
| Suven Pharmaceuticals Limited | 1.4 Billion INR | -252.365% |
| Themis Medicare Limited | 1.12 Billion INR | -339.061% |
| Unichem Laboratories Limited | 6.72 Billion INR | 26.509% |
| Vaishali Pharma Limited | 84.02 Million INR | -5782.422% |
| Wanbury Limited | 978.96 Million INR | -404.914% |
| Windlas Biotech Limited | 1 Billion INR | -391.097% |
| ZIM Laboratories Limited | 1.01 Billion INR | -387.923% |
| Ind-Swift Laboratories Limited | 2.12 Billion INR | -132.698% |
| Ipca Laboratories Limited | 18.98 Billion INR | 73.968% |
| Sun Pharmaceutical Industries Limited | 154.18 Billion INR | 96.794% |
| Venus Remedies Limited | 1.91 Billion INR | -157.944% |
| Sakar Healthcare Limited | 204.07 Million INR | -2322.072% |
| Aurobindo Pharma Limited | 55.65 Billion INR | 91.119% |
| Divi's Laboratories Limited | 14.17 Billion INR | 65.117% |
| AstraZeneca Pharma India Limited | 2.47 Billion INR | -99.836% |
| Mankind Pharma Limited | 29.27 Billion INR | 83.114% |
| Sequent Scientific Limited | 2.9 Billion INR | -70.34% |
| Laurus Labs Limited | 11.9 Billion INR | 58.497% |
| Neuland Laboratories Limited | 2.92 Billion INR | -68.716% |
| J. B. Chemicals & Pharmaceuticals Limited | 14.79 Billion INR | 66.585% |
| Glenmark Pharmaceuticals Limited | 46.95 Billion INR | 89.472% |
| Zydus Lifesciences Limited | 125.21 Billion INR | 96.052% |
| Amrutanjan Health Care Limited | 2.09 Billion INR | -136.048% |
| Wockhardt Limited | 8.48 Billion INR | 41.711% |
| Bal Pharma Limited | 555.62 Million INR | -789.616% |
| Dr. Reddy's Laboratories Limited | 95.87 Billion INR | 94.845% |
| Bliss GVS Pharma Limited | 1.41 Billion INR | -248.285% |
| Par Drugs and Chemicals Limited | 58.28 Million INR | -8380.199% |
| Caplin Point Laboratories Limited | 2.17 Billion INR | -127.314% |
| Shilpa Medicare Limited | 3.33 Billion INR | -48.251% |
| Valiant Laboratories Limited | 138.02 Million INR | -3481.088% |
| Ajanta Pharma Limited | 30.46 Billion INR | 83.774% |
| Aarey Drugs & Pharmaceuticals Limited | 14.21 Million INR | -34677.598% |
| Granules India Limited | 10.31 Billion INR | 52.07% |
| Medicamen Biotech Limited | 335.16 Million INR | -1374.769% |
| Syncom Formulations (India) Limited | 345.63 Million INR | -1330.112% |
| Piramal Enterprises Limited | 63.65 Billion INR | 92.235% |
| Torrent Pharmaceuticals Limited | 21.42 Billion INR | 76.926% |
| NATCO Pharma Limited | 10.05 Billion INR | 50.856% |
| Suven Life Sciences Limited | 109.75 Million INR | -4403.818% |
| Krebs Biochemicals & Industries Limited | 46.15 Million INR | -10609.204% |
| Strides Pharma Science Limited | 9.16 Billion INR | 46.051% |
| Indoco Remedies Limited | 12.06 Billion INR | 59.018% |
| Alpa Laboratories Limited | 127.38 Million INR | -3780.468% |
| Lasa Supergenerics Limited | 291.17 Million INR | -1597.59% |
| Sun Pharma Advanced Research Company Limited | 3.07 Billion INR | -60.652% |